Leonard Zehr, Author at BioTuesdays

Feature

VoxNeuro is giving the brain a voice through cognitive health assessment

VoxNeuro’s software as a medical device (SaMD) is transforming cognitive health assessment as it pushes the boundaries of our understanding of the brain to improve decision-making by clinicians and patients.

October 11, 2022

Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human studies in end-stage renal disease patients...

October 4, 2022

Developments

VoxNeuro, CAF in study to measure training-related sub-concussive exposure

VoxNeuro, a closely-held software-as-a-medical-device (SaMD) brain health company, has partnered with the Canadian Armed Forces (CAF) to study the cognitive effects following intense military training regimens designed...

September 28, 2022

Feature

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Kiora Pharmaceuticals (NASDAQ:KPRX) expects to release Phase 1b interim data at the beginning of 2023 from its flagship intravitreal injection to potentially restore vision in patients with retinitis pigmentosa, a rare...

September 27, 2022

Developments

Maxim survey finds two-thirds of respondents planning to attend JMP

A survey of 150 people to a recent Maxim Group survey about the upcoming J.P. Morgan Healthcare Conference found that 69% of respondents are planning to attend the conference in person, while 52% would choose in person...

September 26, 2022

Feature

Blue Water Vaccines designing vaccines against infectious diseases

Blue Water Vaccines (NASDAQ:BWV) is building an early-stage pipeline of six transformational vaccine candidates targeting important infectious diseases, including inner ear infections, influenza, norovirus, rotavirus...

September 20, 2022

Developments

Zucara secures Phase 2 funding for hypoglycemia trial

Closely-held Zucara Therapeutics’ positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01 to prevent hypoglycemia in people with Type 1 diabetes, which is...

September 19, 2022

Developments

Profound Medical realigns commercial organization to support continued growth

Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...

September 15, 2022

Developments

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Sigyn Therapeutics (OTCQB:SIGY) plans to pursue first-in-human feasibility studies of its Sigyn Therapy in end-stage renal disease (ESRD) patients suffering from excess inflammation and/or endotoxemia. Sigyn Therapy is...

September 14, 2022

Developments

Fresh Tracks starts Phase 1 MAD study of DYRK1A inhibitor

Fresh Tracks Therapeutics (NASDAQ:FRTX), formerly Brickell Biotech, initiated the multiple ascending dose (MAD) portion of the ongoing Phase 1 clinical trial in Canada, evaluating FRTX-02, its lead drug candidate, in...

September 13, 2022

Author - Leonard Zehr

VoxNeuro is giving the brain a voice through cognitive health assessment

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

VoxNeuro, CAF in study to measure training-related sub-concussive exposure

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Maxim survey finds two-thirds of respondents planning to attend JMP

Blue Water Vaccines designing vaccines against infectious diseases

Zucara secures Phase 2 funding for hypoglycemia trial

Profound Medical realigns commercial organization to support continued growth

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Fresh Tracks starts Phase 1 MAD study of DYRK1A inhibitor

General

More